Ajanta Pharma Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,794 Cr +32.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AP

Ajanta Pharma

Q3 FY26Pharmaceuticals & Biotechnology

Ajanta Pharma Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,375Cr
+20% YoY
+1.6% QoQ
Net profit
₹274Cr
+17.6% YoY
+5.4% QoQ
Margin
28%
0 pp YoY
+4 pp QoQ
Price₹3,640
Market cap₹45.5K Cr
P/E40.1

The short version

Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.

From Ajanta Pharma's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Ajanta Pharma expects continued healthy growth momentum across business segments.
  • India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years.
  • U.S. generics showed 52% growth in Q3 FY26; 8 product launches in last 12 months; double-digit growth expected in FY27 but likely at a slower pace than FY26.
  • Asia branded business projected to deliver mid-single-digit to high-single-digit growth, with some softness expected in certain markets.
  • Africa branded business expected to post low-double-digit growth.
  • GLP-1 products set to launch in emerging markets from FY27, with first revenue expected around FY28.
  • Plans to expand into new geographies (e.g., Latin America) and therapeutic segments to support growth towards $1 billion revenue.

2 more points from Ajanta Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores. (Page 5)
  • Continued strategic investment in products, brand, and people across the branded generic portfolio is ongoing, as reflected by a 24% increase in other expenses compared to last year. (Page 5)
  • There is an increased thrust on acquisitions, which might influence future payout decisions and strategic direction. The Board will decide on this after Q4 results. (Page 9)

2 more points from Ajanta Pharma's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion primarily focuses on: - Revenue growth and segments - Market expansion and sales force additions - Product launches and partnerships, especially related to GLP-1 products

2 more points from Ajanta Pharma's call on order book

Create a free account to keep reading this call

Ajanta Pharma — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Ajanta Pharma Q3 FY26 results — key figures

Ajanta Pharma Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue1,3751,146+20%1,354+1.6%
Operating profit (EBITDA)382321+19%328+16.5%
Operating margin28%28%0 pp24%+4 pp
Profit before tax359307+16.9%341+5.3%
Net profit (PAT)274233+17.6%260+5.4%
EPS (₹)21.9118.64+17.5%20.83+5.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹388 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Ajanta Pharma and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Ajanta Pharma Q3 FY26 results?

Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.

What is Ajanta Pharma share price analysis?

Ajanta Pharma currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ajanta Pharma planning capital expenditure?

Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores.

Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.